Swiss multinationals see gold in China's silver economy
China's aging population is proving an opportunity for some Swiss healthcare providers.
Source: swissinfo.ch
Stay updated with breaking news from Nerys Avery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
China's aging population is proving an opportunity for some Swiss healthcare providers.
Turkey and Novartis are in a stand-off over approval of Zolgensma - a $2.1 million gene therapy.
Swiss pharma giant Novartis launched Zolgensma five years ago with a price tag of $2.1 million. What happened to it?
As more multi-million-dollar drugs come on the market, there are growing calls for transparency on drug pricing.
As more multi-million-dollar drugs come on the market, there are growing calls for transparency on drug pricing.